If you had bought 10x Genomics on 13 November 2025, the past year now looks very different. Investors who held 10x Genomics over the past year are up 266.2%, including dividends. That result lands after Atera shipments began, earnings reports mixed falling license income with stronger consumables, and new cancer research collaborations grabbed headlines. The harder question is what early buyers were actually weighing back then, product excitement or concerns about funding pressure and competition.
On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.
This theme extends beyond 10x Genomics. See which of 36 healthcare AI stocks may still merit a closer look.
The Argument You Would Have Been Weighing On 10x Genomics
The shares cost US$16.35 at the start of the period, which left 10x Genomics investors choosing between two very different stories about what came next.
On the bullish side, the August 2025 Narrative put Fair Value at US$18, about 10% above the start price. This was built on an assumption of 7.9% annual revenue growth as advanced genomics tools broadened use in precision medicine.
The bearish August 2025 view set Fair Value at US$9, 45% below the start price. It focused on a risk that revenue might grow only 0.9% a year while US academic and government funding stayed under pressure.
What The Evidence Did To The 10x Genomics Argument
Atera moving from launch to global shipments, along with the Proteintech Genomics deal and new cancer collaborations, clearly leaned toward the more optimistic 10x Genomics story that emphasized product breadth and consumables. Reported Q3 2026 revenue of US$150.7m versus US$149.0m a year earlier and a narrower loss lifted net margin to -12.9%, yet profitability remained unproven.
The lesson here is simple. When a thesis rests on tools adoption and recurring consumables, it is important to track segment commentary, order books and net margin together, rather than assuming headline product launches alone will do the heavy lifting.
What Today's 10x Genomics Price Already Assumes
Today 10x Genomics trades at US$58.19 after a 266.2% gain over the past year. The bearish analyst Narrative on Simply Wall St places its Fair Value below that level, framing the current tag as a full one rather than a clear mispricing.
That Narrative leans on a question. Does Atera driven spatial demand and AI linked workflows translate into enough durable consumables volume to support this valuation if academic budgets stay tight and instrument orders stay choppy?
"The numbers imply that the share price already embeds strong confidence in Atera driven spatial growth, AI linked demand for complex experiments, and progress toward clinical applications, which leaves limited room for disappointment if any of these drivers underperform."
The price and this Narrative do not agree. → Uncover what this Narrative says 10x Genomics is actually worth
Another Way To Play Genomics
10x Genomics points you toward cutting edge tools. Your next step might be asking who turns those discoveries into actual treatments.
Where 10x focuses on measurement and analysis, this other business concentrates on therapies. It develops drugs and vaccines that rely on a steady stream of biological insight.
The need is simple. As research uncovers more precise disease targets, pharmaceutical pipelines require a wider range of targeted medicines and supporting platforms.
This firm is trying to meet that demand with new treatments, new modalities and AI supported discovery. The open question is how far that shift can reshape its future mix.
It is written up in full, assumptions and all. → Explore the Narrative that puts this company 26% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com